CryoStor® CS10
cGMP-manufactured, animal component-free, defined cryopreservation medium with 10% DMSO
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Overview
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (24)
Publications (125)
Generation of effector CD4+ T cells from human iPSC.
Stem cell reports 2026 Sep
Abstract
Off-the-shelf T cell therapies could be transformative in chimeric antigen receptor (CAR) therapies for cancers and treatment of chronic inflammatory diseases. However, challenges remain in generating CD4+ T cells from induced pluripotent stem cells (iPSCs). We describe a key role for the withdrawal of Notch ligand during T cell receptor stimulation of CD4/CD8 double-positive progenitors allowing access to the CD4+ lineage in iPSC T cells (iCD4+ T cells). Functional analyses of iCD4+ T cells by using a novel high-parameter cytometry by time-of-flight (CyTOF) intracellular cytokine panel revealed canonical Th1 cytokine signatures and cells producing varying combinations of other cytokines, including IL-4, IL-8, and IL-13. Single-cell RNA sequencing of iCD4+ T cells demonstrated a transcriptional signature similar to human peripheral CD4+ T cells. We believe this robust yet simple platform represents a key step toward off-the-shelf iCD4+ T cell therapies with utility for the treatment of a panoply of diseases including cancer and inflammatory autoimmune disorders.
Innate Immunocompetent hiPSC-Derived Neurospheroids Capture Early CNS Responses to rAAV.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Sep
Abstract
Gene therapies using adeno-associated viruses (AAVs) for central nervous system (CNS) disorders face challenges because host immune responses are not represented in classical preclinical models. Here, we present a human-induced pluripotent stem cell (hiPSC)-derived innate immunocompetent 3D CNS model that recapitulates neuroinflammatory hallmarks, serving as a platform for preclinical gene therapy development. By utilizing various scales of stirred-tank bioreactor systems, we generated neurospheroids (iNSpheroids) composed of neurons, astrocytes, and oligodendrocytes, alongside microglial cells (iMGLs) to mimic the neuroimmune axis. These systems enabled large-scale production of iNSpheroids and subsequent miniaturization for co-culture experiments and screening of inflammatory stimuli, while maintaining a highly controlled environment. The iMGL-iNSpheroids demonstrated active neuron-microglia crosstalk and exhibited distinct inflammatory responses to a series of neuroinflammatory factors. iMGL-iNSpheroids mounted an early response to rAAV9, which is underscored by the activation of inflammatory pathways (e.g., TNF-via NF-κB activation) in glial cell populations. This model offers a valuable tool to dissect neuroinflammatory mechanisms, accelerating gene therapy development.
A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions.
NPJ precision oncology 2026 Sep
Abstract
Macrophages are among the most abundant immune cells in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) and play a key role in regulating the immunosuppressive niche that facilitates tumor growth. Although recent three-dimensional (3D) culture systems using patient-derived materials have advanced our understanding of tumor biology, most models lack key cellular TME components and thus fail to capture tumor-immune cell interactions. To address this gap, we developed an in-vitro 3D co-culture model incorporating PDAC patient-derived organoids (PDOs) and macrophages within a synthetic hydrogel matrix. We optimized culture conditions by tuning medium and matrix conditions to support both cell lineages. Flow cytometry and transcriptomic analyses revealed that initially undifferentiated macrophages adopt an M2-like profile upon exposure to PDAC PDOs in starPEG-heparin hydrogels, mirroring the macrophage phenotypes observed by multiplex immunohistochemistry in the matched primary PDAC tissues. Cytokine secretome profiling revealed PDO-specific differences, indicating distinct underlying macrophage polarization subtypes. Collectively, our starPEG-heparin hydrogel-based 3D co-culture enables hypothesis-driven and physiologically relevant studies of tumor-macrophage interactions and may advance immune-modulatory treatment strategies in patients with PDAC.
Related Products
Related Products
Quality Statement:
CRYOSTOR PRODUCTS MEET USP STERILITY AND USP ENDOTOXIN TESTING STANDARDS, AND ARE MANUFACTURED UNDER CGMP.
CRYOSTOR PRODUCTS MEET USP STERILITY AND USP ENDOTOXIN TESTING STANDARDS, AND ARE MANUFACTURED UNDER CGMP.
